Why Similar Age and AMH Results Can Lead to Different IVF Plans

Two people can be the same age, hold AMH reports that look almost identical, and still leave consultations with noticeably different IVF plans. That is not necessarily a sign that one clinic is better informed than the other. It usually means the plan was built from more than two numbers.

Age and AMH are useful starting points. They help a clinician think about how many eggs might be available and how age relates to chromosome risk in embryos. Neither one, on its own, tells the whole story of how someone will respond to stimulation, what protocol suits them, or whether genetic testing of embryos belongs in their plan.

What AMH measures, and what it does not

AMH (anti-Müllerian hormone) is generally used as a marker of ovarian reserve — a rough indication of how many small follicles are present and how the ovaries may respond to stimulation. It is a quantity signal, not a quality signal.

AMH does not measure:

• the chromosomal status of individual eggs;
• whether an egg will fertilise;
• whether an embryo will implant;
• whether a pregnancy will be ongoing.

This is why a low AMH does not automatically mean pregnancy is impossible, and a high AMH does not automatically mean a straightforward cycle. A high AMH can also sit alongside a diagnosis such as polycystic ovary syndrome (PCOS), which changes how stimulation is planned and how ovarian hyperstimulation syndrome (OHSS) risk is managed.

Age works differently. It is one of the factors clinicians weigh when discussing embryo chromosome risk and when PGT-A might be raised as an option. But age is a population-level signal, not a prediction about any one person’s embryos. For a fuller discussion of how age interacts with embryo testing, see PGT for advanced maternal age in Thailand.

The inputs a clinician weighs beyond age and AMH

When a plan differs between two people with similar numbers, the difference usually comes from clinical context — the history, examinations and prior treatment experience that sit around the lab results.

Ovarian findings on ultrasound

Antral follicle count (AFC) is measured on ultrasound and is often read alongside AMH. The two usually agree, but not always. When they diverge, the clinician has to decide which signal to trust more for that person, and that judgement can shift the starting dose.

Hormone results and cycle day

FSH, estradiol, thyroid function and other results, interpreted against the day of the cycle they were drawn, add context. A result read on the wrong cycle day can be misleading, which is one reason dated, complete records matter.

Previous stimulation response

If someone has already had a cycle, the number of eggs retrieved, the dose used, how the ovaries responded and whether OHSS occurred are often more informative than any baseline number. A previous poor or exaggerated response is a strong reason to change protocol.

Male factor and semen parameters

Semen analysis findings influence whether standard IVF or ICSI is discussed, and whether additional sperm selection techniques are considered. These decisions sit alongside, not inside, the AMH result.

Uterine and pelvic factors

Fibroids, polyps, adenomyosis, endometriosis, the appearance of the lining and any planned surgical review can change timing and whether a fresh or frozen transfer is preferred.

Endocrine and other diagnoses

PCOS, thyroid conditions and other endocrine issues can affect stimulation strategy, OHSS risk and when a cycle should start.

Prior pregnancy loss or genetic findings

A history of loss, a known inherited condition in the family, or a chromosomal rearrangement carried by a parent changes the conversation entirely. PGT-M addresses a known monogenic condition, and PGT-SR addresses chromosomal structural rearrangements; both are designed around a specific history rather than offered generically. The HFEA overview of PGT-M and PGT-SR explains that these tests answer different questions and should be discussed with a treating team and genetic counsellor. A comparison of how PGT-A and PGT-M differ is covered in PGT-A vs PGT-M in Thailand.

Patient priorities and practical constraints

Two people with the same clinical picture may still choose different plans because of cost, travel time, work commitments, willingness to bank embryos across several cycles, or views on embryo testing. These are legitimate inputs, not afterthoughts.

How those inputs change concrete plan elements

The same baseline numbers can lead to different choices at several decision points:

Plan element	What can shift it
Starting gonadotropin dose	AMH, AFC, prior response, PCOS diagnosis, age
Protocol choice (antagonist, long agonist, mild)	Prior response, OHSS risk, endometriosis, scheduling
Adjuvant add-ons	Individual history and the clinician’s reading of the evidence
Trigger strategy and OHSS management	Follicle number, estradiol level, PCOS, prior OHSS
Fresh versus freeze-all transfer	Lining, hormone levels, OHSS risk, PGT-A plans
Number of cycles before transfer	Embryo yield so far, banking goals, age, cost and travel
Whether PGT-A is discussed	Age, prior loss, prior aneuploidy, patient priorities

None of these rows can be decided from age and AMH alone. That is the practical reason two similar-looking reports can produce different plans.

A short worked contrast

Consider two hypothetical patients, both 36 and both with an AMH in a similar mid-range band. This is an illustration of how context changes decisions, not a description of real cases or expected outcomes.

Patient A has an AFC that matches her AMH, regular cycles, no prior IVF, a normal semen analysis and no pelvic findings. Her clinician might discuss a standard antagonist protocol at a moderate starting dose, a fresh transfer if her lining and hormone levels allow, and PGT-A as an option to weigh rather than a default.

Patient B has a lower AFC than her AMH would suggest, a previous cycle with a modest egg yield on a standard dose, and a partner with a semen analysis that raises the question of ICSI. Her clinician might discuss a higher starting dose or a different protocol, a freeze-all approach to preserve options, and a conversation about whether to bank embryos across more than one cycle before transfer.

Same age. Similar AMH. Different plans — because the plan was built from the context, not the headline numbers.

Where PGT-A fits, and where it does not

PGT-A assesses chromosome number in cells sampled from an embryo. The HFEA patient information on PGT-A notes that testing has limitations and can produce incorrect findings, and that a result does not guarantee a successful pregnancy or a healthy child. Biopsy itself carries a risk: the HFEA PGT-A FAQ states that embryo biopsy can cause damage and prevent further development.

Results also need careful reading. A mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample; technical factors can contribute, and a sampled result does not establish the cell composition of the whole embryo. The ASRM committee opinion on mosaic PGT-A results recommends discussing such results and their uncertainty with the treating clinician and a genetic counsellor.

So PGT-A is a discussion, not a checkbox. Whether it is raised, and how much weight it carries, depends on age, history, embryo numbers and what matters to the patient. How results are reported is covered in how to read PGT-A results.

Records that make a remote review more useful

If you are comparing plans or seeking a remote opinion, the quality of the review depends on the quality of the records. A useful set usually includes:

• dated AMH, FSH, estradiol and thyroid results, with the cycle day noted;
• ultrasound reports showing antral follicle count and any pelvic findings;
• semen analysis reports with dates;
• prior stimulation records: protocol, doses, follicle counts, trigger, eggs retrieved, fertilisation and embryo outcomes;
• any OHSS history or cycle cancellation reasons;
• prior pregnancy, loss or genetic testing reports;
• a short written summary of your own priorities: timing, travel, budget range and views on embryo testing.

Organising these before a consultation makes the conversation more specific. Guidance on preparing records is in how to organise medical records for a remote fertility review.

Questions worth putting to your clinician

These are neutral prompts for a licensed clinician, who is the right person to interpret your results and recommend a plan:

• Which findings in my history are shaping your recommended protocol, and why?
• How do my AMH and antral follicle count compare, and which are you weighting more?
• What would change your starting dose or protocol if my response differs from expectation?
• What is my OHSS risk, and how would you manage it?
• Would you recommend a fresh or frozen transfer for me, and what would change that?
• Is PGT-A relevant to my situation, and what are the limitations in my case?
• If I need more than one cycle, how would we plan that around my travel and budget?

Thailand PGT can help organise records, prepare questions and coordinate appointments or remote consultations. The coordination service does not interpret results, diagnose or recommend protocols — those conversations belong with your treating clinician. Scope and any fees are confirmed individually.